Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL). The names of the study drugs involved in this study are: * Venetoclax (a type of inhibitor) * Rituximab (a type of antibody)

Trial Details

NCT ID
NCT06510309
Phase
PHASE2
Sponsor
Gottfried von Keudell, MD PhD
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Venetoclax
  • Rituximab
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participants must have histologically confirmed Marginal Zone Lymphoma
  • Patients must have measurable disease as defined by at least one lymph node ≥1.5 cm or spleen \> 13 cm
  • Patients with intestinal MALT lymphoma must have disease that is detectable by EGD or colonoscopy with biopsy
  • Patients with gastric MALT lymphoma must be h. pylori negative. Patients who are h. pylori positive are allowed if they have failed a trial of h. p…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →